[go: up one dir, main page]

PE20050575A1 - Formulaciones farmaceuticas que conservan el sabor con caracteristicas farmaceuticas mejoradas - Google Patents

Formulaciones farmaceuticas que conservan el sabor con caracteristicas farmaceuticas mejoradas

Info

Publication number
PE20050575A1
PE20050575A1 PE2004001067A PE2004001067A PE20050575A1 PE 20050575 A1 PE20050575 A1 PE 20050575A1 PE 2004001067 A PE2004001067 A PE 2004001067A PE 2004001067 A PE2004001067 A PE 2004001067A PE 20050575 A1 PE20050575 A1 PE 20050575A1
Authority
PE
Peru
Prior art keywords
flavor
pradofloxacin
pharmaceutical
preserve
refers
Prior art date
Application number
PE2004001067A
Other languages
English (en)
Inventor
Patrick Bosche
Sabine Becker
Venkata-Rangarao Kanikanti
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of PE20050575A1 publication Critical patent/PE20050575A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA SOLIDA QUE COMPRENDE: a) UN PRINCIPIO FARMACEUTICAMENTE ACTIVO SELECCIONADO DE ACIDO 1-CICLOPROPIL-6-FLUORO-1,4-DIHIDRO-4-OXO-7-(4-ETIL-1-PIPERAZINIL)-QUINOLIN-3-CARBOXILICO (ENROFLOXACINO), PRADOFLOXACINO, UNA SAL DEL PRADOFLOXACINO O UN HIDRATO DE PRADOFLOXACINO O DE SUS SALES; UN AROMATIZANTE Y UN SABORIZANTE Y AL MENOS UN 1,5% DE PESO DE DIOXIDO DE SILICIO MUY DISPERSABLE RESPECTO AL PESO TOTAL DE LA FORMULACION. SE REFIERE TAMBIEN A PROCEDIMIENTOS PARA PREPARAR LA FORMULACION FARMACEUTICA SOLIDA CON LOS QUE SE GRANULA EL SABORIZANTE CON EL DIOXIDO DE SILICO MUY DISPERSO ASI COMO UNO O MAS PRINCIPIOS ACTIVOS Y SUSTANCIAS AUXILIARES Y ADITIVOS FARMACEUTICAMENTE ACEPTABLES
PE2004001067A 2003-11-04 2004-11-03 Formulaciones farmaceuticas que conservan el sabor con caracteristicas farmaceuticas mejoradas PE20050575A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10351448A DE10351448A1 (de) 2003-11-04 2003-11-04 Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften

Publications (1)

Publication Number Publication Date
PE20050575A1 true PE20050575A1 (es) 2005-10-27

Family

ID=34559323

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001067A PE20050575A1 (es) 2003-11-04 2004-11-03 Formulaciones farmaceuticas que conservan el sabor con caracteristicas farmaceuticas mejoradas

Country Status (30)

Country Link
US (2) US7858120B2 (es)
EP (2) EP1682144B1 (es)
JP (1) JP4892351B2 (es)
KR (2) KR20120093299A (es)
CN (2) CN1972687B (es)
AR (2) AR046226A1 (es)
AT (1) ATE454891T1 (es)
AU (1) AU2004286785B2 (es)
BR (1) BRPI0416188A (es)
CA (1) CA2544344C (es)
CR (1) CR8371A (es)
CY (2) CY1110541T1 (es)
DE (2) DE10351448A1 (es)
DK (1) DK1682144T3 (es)
ES (1) ES2337793T3 (es)
HR (1) HRP20100189T1 (es)
IL (1) IL175147A (es)
LU (1) LU91882I2 (es)
MY (1) MY149864A (es)
NO (1) NO339326B1 (es)
NZ (1) NZ546921A (es)
PE (1) PE20050575A1 (es)
PL (1) PL1682144T3 (es)
PT (1) PT1682144E (es)
RU (1) RU2377018C2 (es)
SI (1) SI1682144T1 (es)
TW (1) TWI343819B (es)
UA (1) UA85691C2 (es)
WO (1) WO2005044271A1 (es)
ZA (1) ZA200603451B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
CN100360131C (zh) * 2006-01-24 2008-01-09 新昌国邦化学工业有限公司 一种掩味恩诺沙星的生产方法
DE102006049520A1 (de) 2006-10-20 2008-04-24 Bayer Healthcare Ag Verfahren zur Herstellung von Pradofloxacin
DE102007004732A1 (de) * 2007-01-31 2008-08-07 Bayer Healthcare Ag Enrofloxacin-Hexahydrat
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
GB0722484D0 (en) * 2007-11-15 2007-12-27 Ucl Business Plc Solid compositions
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
US20110223297A1 (en) * 2010-03-12 2011-09-15 Pepsico., Inc. Anti-Caking Agent for Flavored Products
ES2848394T3 (es) * 2012-12-19 2021-08-09 Bayer Animal Health Gmbh Comprimidos que tienen aceptación mejorada y buena estabilidad durante el almacenamiento
WO2015042596A1 (en) * 2013-09-23 2015-03-26 Kindred Biosciences, Inc Treatment of atopic dermatitis in non-human animals
WO2017188361A1 (ja) * 2016-04-27 2017-11-02 富山化学工業株式会社 トスフロキサシントシル酸塩を含む錠剤
TWI727036B (zh) * 2016-04-27 2021-05-11 日商富山化學工業股份有限公司 包含甲苯磺酸托氟沙星、崩解劑及酸性胺基酸之錠劑
CN105997908B (zh) * 2016-06-03 2019-06-21 湖北回盛生物科技有限公司 一种马波沙星牛肉风味片及其制备方法
CA3098060A1 (en) 2018-04-25 2019-10-31 Bayer Animal Health Gmbh Process for the hydrolysis of quinolone carboxylic esters

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA413698A (en) * 1943-07-06 Frederick Dauster John Breathing valve
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (es) 1985-09-18 1990-05-05 Pfizer
DE3719764A1 (de) * 1987-06-13 1988-12-22 Bayer Ag Ionenaustauscherharze beladen mit chinoloncarbonsaeurederivaten, ihre herstellung und verwendung
US4910023A (en) * 1988-06-09 1990-03-20 Warner-Lambert Company Drug in combination with flavor masking agent and method for making same
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
US5256699A (en) * 1988-10-18 1993-10-26 Ciba-Geify Corporation Dispersible tablet formulation of diclofenac acid free base
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5328908A (en) * 1988-10-24 1994-07-12 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial quinolone thioureas
WO1994028870A1 (en) 1993-06-04 1994-12-22 Warner-Lambert Company Preparations containing silicon dioxide to improve the taste thereof
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
EP0725037B2 (de) 1995-02-04 2012-04-25 Evonik Degussa GmbH Granulate auf Basis von pyrogen hergestelltem Siliciumdioxid, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2247020C (en) 1996-02-23 2005-11-08 Bayer Aktiengesellschaft Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives
US20010018417A1 (en) 1996-07-01 2001-08-30 Carson James W. Virginiamycin mixture
GB9616536D0 (en) 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
DE19633480A1 (de) * 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6607754B1 (en) * 1997-07-11 2003-08-19 Upsher-Smith Laboratories, Inc. Delivery of Hypericum perforatum (St. John's Wort) in tablet form
JP2002505269A (ja) 1998-03-06 2002-02-19 エウランド インターナショナル ソシエタ ペル アチオニ 急速崩壊錠剤
US6419953B1 (en) * 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
HU227070B1 (en) * 1999-08-11 2010-06-28 Egis Gyogyszergyar Nyilvanosan Immediate release pharmaceutical composition containing ciprofloxacin and process for its production
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
HUP0204417A3 (en) 2000-03-03 2005-03-29 Ranbaxy Lab Ltd Oral ciprofloxacin-composition of controlled release
DE10031044A1 (de) * 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
EP1247456A3 (en) * 2001-02-28 2003-12-10 Pfizer Products Inc. Palatable pharmaceutical compositions for companion animals
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US20030235618A1 (en) * 2001-10-22 2003-12-25 Taro Pharmaceutical Industries Ltd. Taste masking spill-resistant formulation
BRPI0308445A2 (pt) * 2002-03-08 2016-08-02 M S Ind Swift Ltd complexos de rápida dissolução, diretamente compressíveis, sem sabor e formulações farmacêuticas dos mesmos
US20030229101A1 (en) * 2002-06-06 2003-12-11 Sherman Bernard Charles Tablets comprising ciprofloxacin hydrochloride
DE10250711A1 (de) 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
HRP20250604T1 (hr) * 2009-11-09 2025-07-18 Wyeth Llc Formulacije tableta neratinib maleata

Also Published As

Publication number Publication date
HRP20100189T1 (hr) 2010-05-31
DE10351448A1 (de) 2005-06-09
AU2004286785A8 (en) 2009-08-13
AU2004286785A1 (en) 2005-05-19
CR8371A (es) 2006-10-10
EP1682144A1 (de) 2006-07-26
CN102335117A (zh) 2012-02-01
US20070196466A1 (en) 2007-08-23
US7858120B2 (en) 2010-12-28
AR046226A1 (es) 2005-11-30
KR20120093299A (ko) 2012-08-22
EP1682144B1 (de) 2010-01-13
CY1110541T1 (el) 2015-04-29
IL175147A0 (en) 2008-04-13
US20110065719A1 (en) 2011-03-17
HK1107008A1 (en) 2008-03-28
PL1682144T3 (pl) 2010-06-30
PT1682144E (pt) 2010-03-09
AU2004286785B2 (en) 2010-08-12
AR108594A2 (es) 2018-09-05
CA2544344A1 (en) 2005-05-19
ATE454891T1 (de) 2010-01-15
CY2011017I1 (el) 2016-12-14
CN1972687B (zh) 2013-01-23
EP2080515A1 (de) 2009-07-22
WO2005044271A1 (de) 2005-05-19
JP2007510001A (ja) 2007-04-19
LU91882I2 (fr) 2013-04-12
MY149864A (en) 2013-10-31
NZ546921A (en) 2009-08-28
ES2337793T3 (es) 2010-04-29
TW200517144A (en) 2005-06-01
CY2011017I2 (el) 2016-12-14
KR20060109910A (ko) 2006-10-23
DK1682144T3 (da) 2010-05-17
BRPI0416188A (pt) 2007-01-23
DE502004010644D1 (de) 2010-03-04
CA2544344C (en) 2013-10-15
ZA200603451B (en) 2007-07-25
UA85691C2 (ru) 2009-02-25
RU2377018C2 (ru) 2009-12-27
SI1682144T1 (sl) 2010-05-31
NO20062605L (no) 2006-07-25
NO339326B1 (no) 2016-11-28
JP4892351B2 (ja) 2012-03-07
KR101325146B1 (ko) 2013-11-07
TWI343819B (en) 2011-06-21
CN1972687A (zh) 2007-05-30
RU2006119294A (ru) 2007-12-27
IL175147A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
PE20050575A1 (es) Formulaciones farmaceuticas que conservan el sabor con caracteristicas farmaceuticas mejoradas
CY1109117T1 (el) Διαμορφωσεις enaιωphmatoς, οι οποιες περιλαμβανουν δραστικον συστατικο, επιφανειακως δρωσαν ουσια poloxamer ή meroxapol και γλυκολη, χρησις του δια την βιομηχανικην παρασκευην φαρμακου προς νοσηλειαν οφθαλμικων διαταραχων
JOP20200222A1 (ar) أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
NO20081844L (no) Terapeutiske forbindelser
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
NO20076635L (no) Krystallinske og andre former for 4-amino-5-fluor-3-[6-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-kinolin-2-on-melkesyresalter
NO20085087L (no) Nye heterocykliske forbindelser
AR083422A1 (es) Composiciones y metodos para tratar la hipertension pulmonar
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
AR107927A1 (es) Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EA201190011A1 (ru) Пероральные лекарственные формы бендамустина
BR112015022385A2 (pt) droga para uma doença respiratória
AU2018263059A1 (en) Compositions and treatment procedures for the treatment of pathogenic infections
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
PE20041022A1 (es) Formulaciones farmaceuticas que comprenden un nuevo agente enmascarante de la amargura
MX2020009711A (es) Combinacion de quinolin-4-carboxamidas y derivados de benzonaftiridina como combinacion de farmacos antipaludicos.
US20080161249A1 (en) Use of Novel Antibacterial Compounds
PA8546201A1 (es) Agentes antibacterianos
PH12021552886A1 (en) Pyrido-pyrimidin derivatives and pharmaceutical composition, for use in preventing or treating pi3 kinase related diseases, comprising same as active ingredient

Legal Events

Date Code Title Description
FC Refusal